LeMaitre Vascular Inc (LMAT) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
LeMaitre Vascular Inc stock (LMAT) is currently trading at $109.99. LeMaitre Vascular Inc PE ratio is 42.19. LeMaitre Vascular Inc PS ratio (Price-to-Sales) is 9.70. Analyst consensus price target for LMAT is $111.00. WallStSmart rates LMAT as Hold.
- LMAT PE ratio analysis and historical PE chart
- LMAT PS ratio (Price-to-Sales) history and trend
- LMAT intrinsic value — DCF, Graham Number, EPV models
- LMAT stock price prediction 2025 2026 2027 2028 2029 2030
- LMAT fair value vs current price
- LMAT insider transactions and insider buying
- Is LMAT undervalued or overvalued?
- LeMaitre Vascular Inc financial analysis — revenue, earnings, cash flow
- LMAT Piotroski F-Score and Altman Z-Score
- LMAT analyst price target and Smart Rating
LeMaitre Vascular Inc
📊 No data available
Try selecting a different time range
LMAT Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · LeMaitre Vascular Inc (LMAT)
LMAT appears undervalued based on the Graham Formula, trading 26% below its estimated fair value of $117.94.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
LeMaitre Vascular Inc (LMAT) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in operating margin, eps growth, profit margin. Concerns around peg ratio and price/sales. Fundamentals are solid but monitor weak areas for improvement.
LeMaitre Vascular Inc (LMAT) Key Strengths (6)
Earnings per share surging 41.40% year-over-year
Keeps $23 of every $100 in revenue as net profit
96.18% of shares held by major funds and institutions
Strong operational efficiency: $22 kept per $100 revenue
Mid-cap company balancing growth potential with stability
Solid profitability: $16 profit per $100 equity
Supporting Valuation Data
LeMaitre Vascular Inc (LMAT) Areas to Watch (4)
Very expensive relative to growth, significant premium
Very expensive at 9.7x annual revenue
Very expensive at 6.2x book value
Solid revenue growth at 15.70% per year
Supporting Valuation Data
LeMaitre Vascular Inc (LMAT) Detailed Analysis Report
Overall Assessment
This company scores 61/100 in our Smart Analysis, earning a C+ grade. Out of 10 metrics analyzed, 6 register as strengths (avg 8.7/10) while 4 fall into concern territory (avg 3.0/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on EPS Growth, Profit Margin, Institutional Own.. Profitability is solid with Return on Equity at 15.80%, Operating Margin at 21.80%, Profit Margin at 23.10%. Growth metrics are encouraging with EPS Growth at 41.40%.
The Bear Case
The primary concerns are PEG Ratio, Price/Sales, Price/Book. Some valuation metrics including PEG Ratio (3.07), Price/Sales (9.70), Price/Book (6.15) suggest expensive pricing. Growth concerns include Revenue Growth at 15.70%, which may limit upside.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether PEG Ratio improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 15.80% currently healthy but needing to be sustained. Third, growth sustainability, with Revenue Growth at 15.70% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a moderate-to-high risk investment. The weight of evidence leans positive, with more strengths than concerns. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Mixed fundamentals with both positives (EPS Growth, Profit Margin) and negatives (PEG Ratio, Price/Sales). A cautious approach is warranted. Monitor for improvement in weak areas before increasing conviction.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
LMAT Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
LMAT's Price-to-Sales ratio of 9.70x trades 82% above its historical average of 5.33x (93th percentile), historically expensive. The current valuation is 23% below its historical high of 12.54x set in Nov 2024, and 880% above its historical low of 0.99x in Jan 2009. Over the past 12 months, the PS ratio has expanded from ~8.6x, reflecting growing market expectations outpacing revenue growth.
Compare LMAT with Competitors
Top MEDICAL INSTRUMENTS & SUPPLIES stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for LeMaitre Vascular Inc (LMAT) · HEALTHCARE › MEDICAL INSTRUMENTS & SUPPLIES
The Big Picture
LeMaitre Vascular Inc is a strong growth company balancing expansion with improving profitability. Revenue reached 250M with 16% growth year-over-year. Profit margins are strong at 23.1%, reflecting pricing power and operational efficiency.
Key Findings
ROE of 1580.0% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
Profit margin of 23.1% and operating margin of 21.8% demonstrate strong pricing power and operational efficiency.
What to Watch Next
Dividend sustainability with a current yield of 73.0%. Watch payout ratio and free cash flow coverage.
Sector dynamics: monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive moves, and regulatory changes that could impact LeMaitre Vascular Inc.
Bottom Line
LeMaitre Vascular Inc offers an attractive blend of growth (16% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About LeMaitre Vascular Inc(LMAT)
NASDAQ
HEALTHCARE
MEDICAL INSTRUMENTS & SUPPLIES
USA
LeMaitre Vascular, Inc. designs, markets, sells, services and supports medical devices and implants for the treatment of peripheral vascular diseases worldwide. The company is headquartered in Burlington, Massachusetts.